The adjusted OR and 95% CI between GSTM1/GSTM1-GSTT1 polymorphisms and HCC risk was significantly increased although heterogeneity (I2GSTT1 = 56.1%, PGSTT1 = 0.002; I2GSTM1-GSTT1 = 59.0%, PGSTM1-GSTT1 = 0.012) still existed. This evidence concerns the gene GSTM1 and hepatocellular carcinoma.